ClinicalTrials.gg
TerminatedNCT01133756Updated Jun 22, 2023Results posted

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

A Phase 1/2 interventional study of Lenvatinib and Carboplatin in Ovarian Cancer, sponsored by Eisai Inc.. Terminated at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Eisai Inc. · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

Why this study was terminated
poor accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Ovarian Neoplasms by Eisai Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Ovarian Neoplasms · Eisai Co., Ltd..

Enrollment
10th of 11
7 · median 41
Started
2010
the only one that year
Phase 1/2
3 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Ovarian Neoplasms by Eisai Co., Ltd., this one is the 10th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 1/2, and was the 7th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

1 of the 11 studies in Ovarian Neoplasms by Eisai Co., Ltd. is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ovarian Neoplasms by Eisai Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study was to determine the maximum tolerated dose (MTD)/recommended Phase II dose of lenvatinib administered in combination with carboplatin and gemcitabine (Phase IB) and to evaluate the safety and tolerability of E7080 administered in combination with carboplatin and gemcitabine compared to carboplatin and gemcitabine alone (Phase II) in participants with platinum-sensitive recurrent ovarian cancer.

Read the detailed description

This open-label, multicenter, randomized study was to consist of a Phase 1b portion: a safety run-in period with 3 doses of lenvatinib administered in combination with carboplatin + gemcitabine; and a Phase II portion: a randomized 2-arm period. Approximately 100 participants with ovarian cancer were to be enrolled in the study (10 to 20 participants in the Phase 1b portion and 80 participants in the Phase II portion). Participants were to participate in either the Phase 1b or the Phase II portion. Participants were to receive study treatment (lenvatinib plus carboplatin + gemcitabine or carboplatin + gemcitabine) for six 21-day cycles (18 weeks). Participants who receive E7080 and experience evidence of clinical benefit (CR, PR, or SD) may continue single agent E7080 beyond 18 weeks, until the occurrence of progressive disease (PD), unacceptable toxicity, withdrawal of consent, or withdrawal by investigator, whichever occurs first.

Initially, an ascending dose schedule starting at lenvatinib 16 mg once daily on Day 1 to Day 21 was chosen for the Phase 1b portion to determine the MTD of lenvatinib administered once daily in combination with carboplatin + gemcitabine; however, due to hematologic toxicity observed in the first cohort, the lenvatinib administration schedule was changed to Days 2 to 21 in Protocol Amendment 2. Continued hematologic toxicity prompted a third protocol amendment, designed to evaluate a lower range of doses starting at lenvatinib 8 mg once daily in Protocol Amendment 3.

After three protocol amendments, recruitment into the Phase 1b portion of the study was very limited, with only one evaluable participant enrolled during the last 5 months of recruitment. Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase II.

Safety was assessed by the monitoring and recording of all adverse events (AEs) and serious adverse events (SAEs); vital signs; Gynecological Oncology Group performance status; clinical laboratory evaluations; physical examinations; and 12-lead electrocardiograms (ECGs).

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants may be in the study only if they meet all of the following criteria.

  1. Female participants greater than or equal to 18 years of age.
  2. or cytologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that was treated with and was sensitive to one prior platinum-based chemotherapy regimen for Stage III or Stage IV disease.
  3. Documentation of biochemical relapse defined by CA125 criteria (measurable or non-measurable by version 1.1 (RECIST criteria), more than six months since completion of platinum-based chemotherapy requiring treatment with further platinum-based chemotherapy. CA125 criteria for relapse Gynecologic Cancer Intergroup (GCIG) criteria are the finding of 2 serum CA125 levels with samples taken at least 1 week apart and no greater than 3 months apart:

    1. greater than or equal to 2 x in participants with an elevated pre-treatment serum CA125 level followed by normalization on treatment and prior to progression OR
    2. greater than or equal to 2 X nadir value for participants with an elevated pre-treatment CA125 that never normalizes).
  4. Gynecological Oncology Group performance status of 0 or 1
  5. greater than or equal to 3 months
  6. Participants must have recovered from effects of any major surgery within 28 days from the first dose of study treatment.
  7. Adequate hematologic, renal, liver, and coagulation system function as defined by laboratory values performed within 21 days prior to initiation of dosing.

    1. (ANC) greater than or equal to 1.5 x 109/L
    2. count greater than or equal to 100 x 109/L
    3. greater than or equal to 9 g/dL
    4. Serum creatinine less than or equal to 1.5 X ULN and/or 50 dL/min
    5. Total serum less than or equal to 1.5 X ULN
    6. Serum (AST/SGOT) or serum alanine transaminase (ALT/SGPT) less than or equal to 2.5 X ULN, and less than or equal to 5 X ULN in cases of liver
    7. PT/ (INR) less than or equal to 1.5 X ULN
    8. h. PTT less than or equal to 1.1 X ULN
  8. Blood pressure must be well-controlled (less than or equal to 140/90 mmHg at screening) with or without antihypertensive medication. Participants must have no history of hypertensive crisis or hypertensive encephalopathy;
  9. Participants should have a negative pregnancy test at screening in pre-menopausal women and women less than 2 years after the onset of menopause. Pre-menopausal women must agree to use an acceptable method of from the time of the negative pregnancy test up to 90 days after the last dose of study drug. Women of non- may be included if they are either surgically sterile or have been for greater than or equal to 1 year;
  10. Before study entry, written must be obtained from participant prior to performing any study-related procedures.

Exclusion criteria

Exclusion Criteria:

Participants will not be entered in the study for any of the following reasons:

  1. Pregnant, breast-feeding, or refusing double barrier , oral contraceptives or avoidance of pregnancy measures;
  2. Prior anti-angiogenic therapy with anti-VEGFR inhibitors; bevacizumab is allowed;
  3. Prior gemcitabine;
  4. Participants with proteinuria greater than 1+ on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with 24-hour urine protein greater than or equal to 1 g/24 hours will be ineligible.
  5. Ovarian nonepithelial cancer, including malignant mixed Mullerian tumors and borderline tumors (e.g., tumors of low malignant potential);
  6. Other within 5 years of randomization, with the exception of adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer, with no subsequent evidence of recurrence;
  7. History of, or known carcinomatous meningitis;
  8. Are currently receiving any other treatment for the tumor (including palliative radiotherapy) aside from control of symptoms;
  9. Received treatment in another clinical study within the 30 days prior to commencing study treatment or participants who have not recovered from side effects of an drug to Grade less than or equal to 1, except for peripheral neuropathy (Grade 1 or 2 are permitted) or alopecia;
  10. Received chemotherapy, biological therapy, hormonal therapy, targeted therapy, or radiotherapy within the 30 days prior to commencing study treatment or have not recovered from all treatment-related toxicities to Grade less than or equal to 1, except for peripheral neuropathy (Grade 1 or 2 are permitted) or alopecia;
  11. Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open , or significant traumatic injury within the 28 days prior to commencing study treatment. Minor surgery such as Portacath placement or skin biopsy is permitted if greater than or equal to 7 days have passed;
  12. The use of anti-coagulants such as Vitamin K antagonists, unfractionated heparin, or low molecular weight heparin;
  13. nausea and vomiting, malabsorption, significant bowel resection, or any other medical condition that would preclude adequate absorption or result in the inability to take oral medication;
  14. Significant cardiovascular impairment (history of congestive heart failure) (NYHA) Grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);
  15. Any history of cerebral vascular accident (CVA) or (TIA) unless they have had no evidence of active disease for at least 6 months prior to randomization
  16. Active hemoptysis (defined as bright red blood of 1/2 teaspoon or more) within the 30 days prior to study entry;
  17. History of abdominal fistula, gastrointestinal perforation, or intrabdominal abscess within the 6 months prior to enrolment;
  18. History of bleeding diathesis or coagulopathy;
  19. History of an allograft requiring ;
  20. Known positive (HIV), known surface antigen positive for hepatitis or C positive;
  21. to E7080 and/or E7080 chemical derivative; or
  22. Have any other uncontrolled infection or medical condition which would interfere with the conduct of the study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Lenvatinib plus carboplatin + gemcitabine

    Phase IB and Phase II

    Drug: Lenvatinib · Drug: Carboplatin · Drug: Gemcitabine

  • Active comparator
    Carboplatin + gemcitabine

    Phase II

    Drug: Carboplatin · Drug: Gemcitabine

Interventions

  • lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.

    Also known as: Lenvima, E7080

  • Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.

  • Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose Limiting Toxicity (DLT)

    DLTs were defined as clinically significant adverse events occurring less than or equal to 21 days after commencing study treatment and considered to be possibly or probably related to study treatment by the Investigator. If 1 DLT occurred at any dose level, the cohort was to be expanded to include a maximum of six evaluable subjects. If 2 DLTs occurred at any dose level, the maximum tolerated dose (MTD) was to be either defined as the preceding dose, or an intermediate dose. To evaluate an intermediate dose, an additional dose cohort could be added to more accurately define the MTD.

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Biomarker CA125-based Overall Response Rate (B-ORR), Within Treatment Group

    Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2. Hence the analysis was not conducted.

    Time frame: Day 1 of every cycle, at end of treatment visit and every 2 months during follow-up period for patients who complete study without progressive disease.

  2. Biomarker-based Proportion of Biomarker-Progression-Free Survival (B-PFS) at Week 12, Within Treatment Group

    Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2. Hence the analysis was not conducted.

    Time frame: Week 12

07

Results

Posted Dec 5, 2016
Limitations and caveats
Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2.

Participant flow

Participant flow — Overall Study
MilestoneLenvatinib 16 mg (Day 1 to Day 21) + Carboplatin + GemcitabineLenvatinib 16 mg (Day 2 to Day 21) + Carboplatin + GemcitabineLenvatinib 8 mg (Day 2 to Day 21) + Carboplatin + Gemcitabine
Started232
Completed 6 cycles100
Completed000
Not completed232
Withdrew: Adverse event121
Withdrew: Investigator decision100
Withdrew: Withdrawal by subject010
Withdrew: Progression of disease001

Outcome measures

PrimaryNumber of Participants With Dose Limiting Toxicity (DLT)

DLTs were defined as clinically significant adverse events occurring less than or equal to 21 days after commencing study treatment and considered to be possibly or probably related to study treatment by the Investigator. If 1 DLT occurred at any dose level, the cohort was to be expanded to include a maximum of six evaluable subjects. If 2 DLTs occurred at any dose level, the maximum tolerated dose (MTD) was to be either defined as the preceding dose, or an intermediate dose. To evaluate an intermediate dose, an additional dose cohort could be added to more accurately define the MTD.

Time frame:
Cycle 1 (21 days)
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicity (DLT)
ParticipantsLenvatinib 16 mg (Day 1 to Day 21) + Carboplatin + GemcitabineLenvatinib 16 mg (Day 2 to Day 21) + Carboplatin + GemcitabineLenvatinib 8 mg (Day 2 to Day 21) + Carboplatin + Gemcitabine
Platelet count decreased100
Thrombocytopenia020
SecondaryBiomarker CA125-based Overall Response Rate (B-ORR), Within Treatment Group

Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2. Hence the analysis was not conducted.

Time frame:
Day 1 of every cycle, at end of treatment visit and every 2 months during follow-up period for patients who complete study without progressive disease.

No measurements were reported for this outcome.

SecondaryBiomarker-based Proportion of Biomarker-Progression-Free Survival (B-PFS) at Week 12, Within Treatment Group

Due to the limited enrollment despite significant diligence to boost enrollment and the complex study design required to manage hematologic toxicity, the study was terminated before the initiation of Phase 2. Hence the analysis was not conducted.

Time frame:
Week 12

No measurements were reported for this outcome.

Adverse events

Collected over For each participant, from the first dose till 30 days after the last dose or up to 18 Sep 2012 or up to 2.5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 16 mg (Day 1 to Day 21) + Carboplatin + Gemcitabine—0/2 (0%)2/2 (100%)
Lenvatinib 16 mg (Day 2 to Day 21) + Carboplatin + Gemcitabine—0/3 (0%)2/3 (66.7%)
Lenvatinib 8 mg (Day 2 to Day 21) + Carboplatin + Gemcitabine—0/2 (0%)1/2 (50%)
Most frequent other events
Showing 10 of 55
Most frequent other events
EventLenvatinib 16 mg (Day 1 to Day 21) + Carboplatin + GemcitabineLenvatinib 16 mg (Day 2 to Day 21) + Carboplatin + GemcitabineLenvatinib 8 mg (Day 2 to Day 21) + Carboplatin + Gemcitabine
ANAEMIABlood and lymphatic system disorders1/22/31/2
NEUTROPENIABlood and lymphatic system disorders1/22/31/2
THROMBOCYTOPENIABlood and lymphatic system disorders1/22/31/2
FATIGUEGeneral disorders1/22/31/2
HYPERTENSIONVascular disorders0/22/30/2
ABDOMINAL DISCOMFORTGastrointestinal disorders0/20/31/2
ABDOMINAL DISTENSIONGastrointestinal disorders0/20/31/2
ABDOMINAL PAINGastrointestinal disorders0/20/31/2
ABDOMINAL PAIN UPPERGastrointestinal disorders1/20/30/2
CONSTIPATIONGastrointestinal disorders1/21/31/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Lenvatinib 16 mg (Day 1 to Day 21) + Carboplatin + GemcitabineLenvatinib 16 mg (Day 2 to Day 21) + Carboplatin + GemcitabineLenvatinib 8 mg (Day 2 to Day 21) + Carboplatin + GemcitabineTotal
<=18 years0000
Between 18 and 65 years0000
>=65 years2327
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 16 mg (Day 1 to Day 21) + Carboplatin + GemcitabineLenvatinib 16 mg (Day 2 to Day 21) + Carboplatin + GemcitabineLenvatinib 8 mg (Day 2 to Day 21) + Carboplatin + GemcitabineTotal
Female2327
Male0000
08

Study locations

1 site
  • Texas Oncology - Austin Central
    Austin, Texas 78731, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Feb 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 4 years 10 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2010
First posted
May 31, 2010
Start
Mar 2010
Primary completionActual
Feb 2012
CompletionActual
Sep 2012
Results delay requested
May 21, 2013
Results first posted
Dec 5, 2016
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01133756
Lead sponsor
Eisai Inc.
Collaborators
PharmaBio Development Inc.
Responsible party
Sponsor
First posted
May 31, 2010
Start date
Mar 2010
Primary completion
Feb 2012
Completion
Sep 2012
Results posted
Dec 5, 2016
Last update
Jun 22, 2023

Study contacts

Harish Dave, MD
study director · Quintiles, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion